早期感染的 HIV-1 包膜 V1-V2 基因型不会增强在高水平表达 α4β7 整合素的细胞中的结合或复制。
Early infection HIV-1 envelope V1-V2 genotypes do not enhance binding or replication in cells expressing high levels of α4β7 integrin.
机构信息
*Department of Medicine, Division of Infectious Disease, Boston University School of Medicine, Boston, MA; and †Dana Farber Cancer Research Center, Boston, MA.
出版信息
J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):249-53. doi: 10.1097/QAI.0b013e3182a06ddd.
Abstract
It has been postulated that HIV-1 envelope properties, such as shorter and less-glycosylated V1-V2 loops commonly observed among non-subtype B early-transmitted viruses, promote utilization of the gut homing integrin α4β7. This property potentially confers an advantage to some HIV-1 variants early after acquisition. We found that replication-competent recombinant viruses incorporating HIV-1 subtype A compact and less-glycosylated early versus chronic phase V1-V2 loops demonstrated no significant difference in binding to α4β7 high CD8⁺ T cells or replication in α4β7 high CD4⁺ T cells. Integrin α4β7 usage does not select for shorter less-glycosylated envelopes during transmission.
摘要
据推测，HIV-1 包膜的特性，如在非 B 亚型早期传播病毒中常见的更短和更少糖基化的 V1-V2 环，促进了肠道归巢整合素 α4β7 的利用。这种特性可能使一些 HIV-1 变体在获得后的早期具有优势。我们发现，复制型重组病毒中整合了 HIV-1 亚型 A 紧凑和更少糖基化的早期与慢性 V1-V2 环，在与高 CD8+T 细胞上的 α4β7 结合或在高 CD4+T 细胞中的复制方面没有显著差异。整合素 α4β7 的使用在传播过程中不会选择更短和更少糖基化的包膜。
相似文献
1
Early infection HIV-1 envelope V1-V2 genotypes do not enhance binding or replication in cells expressing high levels of α4β7 integrin.早期感染的 HIV-1 包膜 V1-V2 基因型不会增强在高水平表达 α4β7 整合素的细胞中的结合或复制。
J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):249-53. doi: 10.1097/QAI.0b013e3182a06ddd.
2
Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.鉴定HIV-1 gp120可变区2和3环中与α4β7整合素受体结合的新区域。
PLoS One. 2015 Dec 1;10(12):e0143895. doi: 10.1371/journal.pone.0143895. eCollection 2015.
3
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.传播/创始者和慢性 C 型 HIV-1 以同等效率使用 CD4 和 CCR5 受体，并且不会被阻断整合素 α4β7 所抑制。
PLoS Pathog. 2012;8(5):e1002686. doi: 10.1371/journal.ppat.1002686. Epub 2012 May 31.
4
Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.1型人类免疫缺陷病毒的V1-V2包膜环序列在感染过程中会扩展并增加糖基化位点，这些修饰会影响抗体中和敏感性。
J Virol. 2006 Oct;80(19):9586-98. doi: 10.1128/JVI.00141-06.
5
Cryptic determinant of α4β7 binding in the V2 loop of HIV-1 gp120.HIV-1 gp120 V2环中α4β7结合的隐秘决定簇。
PLoS One. 2014 Sep 29;9(9):e108446. doi: 10.1371/journal.pone.0108446. eCollection 2014.
6
Envelope glycoprotein binding to the integrin α4β7 is not a general property of most HIV-1 strains.包膜糖蛋白与整合素α4β7结合并非大多数HIV-1毒株的普遍特性。
J Virol. 2014 Sep;88(18):10767-77. doi: 10.1128/JVI.03296-13. Epub 2014 Jul 9.
7
Integrin αβ expression on peripheral blood CD4 T cells predicts HIV acquisition and disease progression outcomes.外周血 CD4 T 细胞整合素 αβ 表达可预测 HIV 感染和疾病进展结果。
Sci Transl Med. 2018 Jan 24;10(425). doi: 10.1126/scitranslmed.aam6354.
8
HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners.新发感染人群及其异性性伴中 HIV-1 包膜复制和 α4β7 的利用情况。
Retrovirology. 2013 Dec 26;10:162. doi: 10.1186/1742-4690-10-162.
9
The Role of Integrin αβ Signaling in Human Immunodeficiency Virus-1 Pathogenesis and Viral Entry in Primary CD4 T Cells As Revealed by Comparative Phosphoproteomic Signatures.整合素 αβ 信号在人类免疫缺陷病毒-1 发病机制和原发性 CD4 T 细胞中病毒进入的作用：比较磷酸化蛋白质组学特征揭示。
OMICS. 2020 Jul;24(7):437-450. doi: 10.1089/omi.2019.0196. Epub 2020 Jun 9.
10
South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication.具有特定V2基序的南非HIV-1 C亚型传播变体在复制过程中对α4β7的依赖性更高。
Retrovirology. 2015 Jun 24;12:54. doi: 10.1186/s12977-015-0183-3.
引用本文的文献
1
Characterization of envelope sequence of HIV virus in children infected with HIV in Vietnam.越南感染艾滋病毒儿童中艾滋病毒包膜序列的特征分析。
SAGE Open Med. 2020 Jun 25;8:2050312120937198. doi: 10.1177/2050312120937198. eCollection 2020.
2
The HIV-1 transmission bottleneck.人类免疫缺陷病毒1型传播瓶颈
Retrovirology. 2017 Mar 23;14(1):22. doi: 10.1186/s12977-017-0343-8.
3
Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs.追踪HIV-1传播：HIV-1传播者与接受者配对的包膜特征
Retrovirology. 2016 Sep 5;13(1):62. doi: 10.1186/s12977-016-0299-0.
4
Integrin α4β7 Expression Increases HIV Susceptibility in Activated Cervical CD4+ T Cells by an HIV Attachment-Independent Mechanism.整合素α4β7表达通过一种不依赖HIV附着的机制增加活化宫颈CD4+ T细胞对HIV的易感性。
J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):509-18. doi: 10.1097/QAI.0000000000000676.
5
South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication.具有特定V2基序的南非HIV-1 C亚型传播变体在复制过程中对α4β7的依赖性更高。
Retrovirology. 2015 Jun 24;12:54. doi: 10.1186/s12977-015-0183-3.
6
Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users.急性和慢性感染注射吸毒者中HIV-1包膜的特征分析。
Retrovirology. 2014 Nov 28;11:106. doi: 10.1186/s12977-014-0106-8.
7
Cellular superspreaders: an epidemiological perspective on HIV infection inside the body.细胞超级传播者：体内HIV感染的流行病学视角
PLoS Pathog. 2014 May 8;10(5):e1004092. doi: 10.1371/journal.ppat.1004092. eCollection 2014 May.
8
HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners.新发感染人群及其异性性伴中 HIV-1 包膜复制和 α4β7 的利用情况。
Retrovirology. 2013 Dec 26;10:162. doi: 10.1186/1742-4690-10-162.
本文引用的文献
1
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.增加 HIV-1 疫苗对具有 Env V2 遗传特征的病毒的功效。
Nature. 2012 Oct 18;490(7420):417-20. doi: 10.1038/nature11519. Epub 2012 Sep 10.
2
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.传播/创始者和慢性 C 型 HIV-1 以同等效率使用 CD4 和 CCR5 受体，并且不会被阻断整合素 α4β7 所抑制。
PLoS Pathog. 2012;8(5):e1002686. doi: 10.1371/journal.ppat.1002686. Epub 2012 May 31.
3
Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.感染过程中的敏感性变化增加了对融合抑制剂而非CCR5受体阻滞剂产生耐药性的可能性。
AIDS Res Hum Retroviruses. 2012 Dec;28(12):1584-93. doi: 10.1089/AID.2011.0319. Epub 2012 Jun 25.
4
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.HIV-1 疫苗功效试验的免疫相关性分析。
N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.
5
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections.与早期或慢性感染相关的 HIV-1B 亚型包膜糖蛋白中的反复出现的特征性模式。
PLoS Pathog. 2011 Sep;7(9):e1002209. doi: 10.1371/journal.ppat.1002209. Epub 2011 Sep 29.
6
The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission.早期传播 HIV gp120 的基因型促进 α (4) β(7)-反应性，揭示 α (4) β(7) +/CD4+ T 细胞是黏膜传播的关键靶标。
PLoS Pathog. 2011 Feb;7(2):e1001301. doi: 10.1371/journal.ppat.1001301. Epub 2011 Feb 24.
7
HIV-1 transmission biology: selection and characteristics of infecting viruses.HIV-1 传播生物学：感染病毒的选择和特征。
J Infect Dis. 2010 Oct 15;202 Suppl 2(Suppl 2):S289-96. doi: 10.1086/655656.
8
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1.整合素 alpha4beta7 与细胞表面 CD4 形成复合物，定义了一个 T 细胞亚群，该亚群极易感染 HIV-1。
Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20877-82. doi: 10.1073/pnas.0911796106. Epub 2009 Nov 20.
9
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.在泰国使用ALVAC和AIDSVAX疫苗预防HIV-1感染。
N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.
10
Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.来自感染慢性期的1型人类免疫缺陷病毒V1至V5包膜变体利用CCR5，并且比感染后早期的变体更有效地融合。
J Virol. 2009 Oct;83(19):9694-708. doi: 10.1128/JVI.00925-09. Epub 2009 Jul 22.
Zotero 插件